# Allogene Therapeutics Inc. (ALLO) fundamentals

Data as of 2026-09-08. NASDAQ, United States. Sector: Healthcare / Biotechnology. Price $1.97, market value $681 million.

## Valuation
- **P/E (trailing): n/a** (negative earnings). Allogene Therapeutics Inc. reported negative earnings over the last twelve months, so the P/E is not meaningful; use price-to-sales, EV/EBITDA and free-cash-flow yield instead.
- **Price / book: 1.6×**. The shares trade at 1.6× book value; book value is a meaningful part of the valuation.
- **Free-cash-flow yield: -15.1%** (5-yr avg -36.1%). Free cash flow is negative: the business is consuming cash, which is normal for heavy investment phases but a warning otherwise.

## Profitability
- **Return on equity: -65.3%**. Return on equity is negative because earnings are negative.
- **Return on assets: -45.9%**. Each dollar of assets produces -45.9% of profit.

## Growth
- **Revenue growth (1 yr): -100.0%** (3-yr -100.0%/yr). Revenue fell 100.0% over the last year.
- **EPS growth (1 yr): 34.1%**. Earnings per share rose 34.1%, faster than revenue, so margins expanded or the share count shrank.

## Financial health
- **Current ratio: 7.93** (quick 7.93). Current assets cover the next year's liabilities 7.93 times.
- **Altman Z-score: 3.28**. A Z-score of 3.28 places the company in the safe zone for bankruptcy risk.
- **Piotroski F-score: 2/9**. 2 of 9 checks pass: weak or deteriorating financials.

## Dividends
- **Dividend: none**. Allogene Therapeutics Inc. does not currently pay a dividend.

## Analyst view
- **Analyst consensus: strong_buy** (9 analysts). 9 analysts cover Allogene Therapeutics Inc.; the consensus is strong_buy, with an average price target of $9.00 (+357% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **Total return (1 yr): 77.5%** (YTD 43.8%, 3-mo 4.8%). The shares are up 77.5% over twelve months including dividends.
- **From 52-week high: -55.8%** (89.4% above the low). Trading 56% below its 52-week high, deep in a drawdown.
- **200-day average: above**. The price sits above its 200-day moving average, the usual definition of an uptrend.
- **RSI (14-day): 47**. An RSI of 47 is neutral.
- **Beta (1 yr): 2.14** (volatility 85%). Beta of 2.14 against the S&P 500: the shares move much more than the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=ALLO · Page: https://foliofundamentals.com/stocks/allo

Not investment advice.